Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
How much more hyperglycemic is my myocardial infarction patient and why does it matter?
Session:
Posters (Sessão 1 - Écran 7) - Miscelânea - Vários Temas
Speaker:
José Lopes De Almeida
Congress:
CPC 2022
Topic:
P. Other
Theme:
37. Miscellanea
Subtheme:
13.2 Acute Coronary Syndromes – Epidemiology, Prognosis, Outcome
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
José Lopes de Almeida; Sofia s. Martinho; Gustavo Campos; João Rosa; João Ferreira; Maria João Ferreira; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Introduction: </span></span></strong><span style="background-color:white"><span style="color:black">Optimal blood glucose concentration target range in myocardial infraction (MI) patients is still a matter of discussion. Both hypoglycemia and hyperglycemia are associated with an increased risk of death and more attention is being given to glycemic variability and how to measure it. We propose two ways of evaluating relative hyperglycemia in MI patients and access its impact on prognosis. </span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Methods: </span></span></strong><span style="background-color:white"><span style="color:black">We retrospectively studied 1117 MI patients admitted to our Coronary Unit for a 10-year period (2004-2014). Admission data and 5-year outcomes were collected. </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="background-color:white"><span style="color:black">Glycemic acute increase (GAI) was calculated estimating the average 3 months glycaemia (3MG) using admission HbA1c and comparing it with admission glycaemia (AG) using the formula: GAI = ((AG-3MG)/AG)*100. </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="background-color:white"><span style="color:black">Glycemic acute decrease (GAD) was calculated by comparing admission and discharge glycaemia (DG) using the formula: GAD = ((AG-DG)/AG)*100.</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Results: </span></span></strong><span style="background-color:white"><span style="color:black">51.9% patients had STEMI and 48.1% NSETMI. 70.9% were male, average age was 68 years, 36.9% had diabetes,75.4% hypertension, 75.4% dyslipidemia,15% were smokers, 8.4% had previous PCI and 3.5% previous CABG.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="background-color:white"><span style="color:black">Average GAI was 24.8% and average GAD was 35.4%. GAI and GAD were both strong predictions of 6 months, 1 year, 3 years and 5 years mortality (p<0.05). GAI and GAD were moderately correlated (Spearson correlation = 0.63, p<0.001, Figure 1). Patients who died after 5 years of follow-up had a 7.9% higher GAI (31.7% vs 23.8%, p<0.001) and a 4.4% higher GAD (39.3% vs 34.9%, p<0.001).</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Conclusions: </span></span></strong><span style="background-color:white"><span style="color:black">The degree of hyperglycemia relative to the patient baseline correlates with prognosis in patients with MI. </span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site